ICI-induced thyroid dysfunction
Conditions
Interventions
The group with thyroid dysfunction following ICI therapy:None
The group without thyroid dysfunction after ICIs treatment:None
Sponsors
Fifth Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years; 2.No gender limitation; 3.Pathologically or clinically diagnosed as a solid tumor; 4.Received at least one cycle of ICI therapy; 5.Thyroid function was tested within three months prior to receiving ICI therapy and was normal, and at least one measurement during follow-up; 6.Had accessible clinical data before treatment with ICIs;
Exclusion criteria
Exclusion criteria: 1.History of thyroid disease, including primary thyroid dysfunction, thyroid cancer, and history of thyroid surgery; 2.Central thyroid dysfunction; 3.Treatments that may affect thyroid function, including antithyroid drugs, thyroid hormones, radioactive iodine-131 therapy, tyrosine kinase inhibitors, and head or neck radiotherapy; 4.Severe heart, liver, and renal insufficiency or autoimmune disorders; 5.Acute or chronic hepatitis B and C viral infections; 6.Tumors affecting the blood system;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between platelet-to-lymphocyte ratio and immune checkpoint inhibitor-induced thyroid dysfunction; | — |
Countries
China
Contacts
Public ContactLi Cong
Fifth Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed